Ohmori S, Ishii I, Kuriya S, Taniguchi T, Rikihisa T, Hirose S, Kanakubo Y, Kitada M
Laboratory of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Chiba University, Japan.
Drug Metab Dispos. 1993 Mar-Apr;21(2):358-63.
Clarithromycin and its metabolites have been examined for their abilities to induce specific form(s) of cytochrome P-450 and metabolite complex formation in rats. Pretreatment of rats with clarithromycin,N-demethyl clarithromycin, clarithromycin N-oxide, and decladinosyl clarithromycin resulted in 48-75% decreases in the amount of 2C11 and 100-600% increases in the amount of 3A1. Clarithromycin and N-demethyl clarithromycin, but not decladinosyl clarithromycin, produced a metabolite complex with cytochrome P-450 in vivo. Activities of testosterone 2 beta- and 6 beta-hydroxylases were increased by administration of clarithromycin and N-demethyl clarithromycin when these activities were measured in the presence of ferricyanide, but not significant induction was observed when measured in the absence of ferricyanide. Clarithromycin N-oxide treatment resulted in the increase in hydroxylation of testosterone not only at the 2 beta- and 6 beta-positions (430 and 190%, respectively), but also at 7 alpha-position (60%), regardless of the presence or absence of ferricyanide. In vitro experiments with hepatic microsomes of dexamethasone-pretreated rats indicated that the metabolites that were modified at the tertiary amino group more efficiently produced the metabolite complex with cytochrome P-450 compared with the parent compound. In contrast, decladinosyl and hydroxylated metabolites had similar or lower capacities for metabolite complex formation than did the parent compound. Clarithromycin and its N-modified metabolites were able to induce 3A1 and form a metabolite complex with cytochrome P-450 in vivo in varying extents. Decladinosyl clarithromycin has a weak inducibility of 3A1 and did not form a metabolite complex with cytochrome P-450 in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
已对克拉霉素及其代谢产物在大鼠体内诱导细胞色素P-450特定形式和代谢物复合物形成的能力进行了研究。用克拉霉素、N-去甲基克拉霉素、克拉霉素N-氧化物和去甲基金刚烷胺预处理大鼠后,2C11的量减少了48-75%,3A1的量增加了100-600%。克拉霉素和N-去甲基克拉霉素(而非去甲基金刚烷胺)在体内与细胞色素P-450形成了代谢物复合物。当在铁氰化物存在下测量时,给予克拉霉素和N-去甲基克拉霉素可增加睾酮2β-和6β-羟化酶的活性,但在无铁氰化物测量时未观察到显著诱导作用。无论有无铁氰化物,克拉霉素N-氧化物处理均导致睾酮不仅在2β-和6β-位(分别增加430%和190%),而且在7α-位(增加60%)的羟化增加。用地塞米松预处理大鼠的肝微粒体进行的体外实验表明,与母体化合物相比,在叔氨基处修饰的代谢物更有效地与细胞色素P-450形成代谢物复合物。相比之下,去甲基金刚烷胺和羟基化代谢物形成代谢物复合物的能力与母体化合物相似或更低。克拉霉素及其N-修饰代谢物在体内能够不同程度地诱导3A1并与细胞色素P-450形成代谢物复合物。去甲基金刚烷胺对3A1的诱导作用较弱,在体内未与细胞色素P-450形成代谢物复合物。(摘要截断于250字)